"There is no scenario that we have not built mitigation plans, and there is no scenario that we haven’t assigned the probability of success. But the truth is that we don’t know what will be, because all of that are right now under active discussion," he said.
Pfizer CEO Albert Bourla says MFN discussions 'are extremely productive'
August 7, 2025 Latest NewsBioPharma
Latest Video
New Stories
-
Cartherics secures Chinese patent to boost immune cell function in solid tumours
August 27, 2025 - - Australian Biotech -
NeuroScientific’s StemSmart MSC therapy shows promise in kidney transplantation
August 27, 2025 - - Australian Biotech -
Starpharma advances dendrimer platform with clinical, commercial, and strategic progress
August 27, 2025 - - Australian Biotech -
Biome achieves breakthrough year with first profit and rapid global expansion
August 27, 2025 - - Australian Biotech -
Neuren doubles profit as DAYBUE royalties and pipeline progress drive growth
August 27, 2025 - - Australian Biotech -
Sigma Healthcare delivers strong first-year results after Chemist Warehouse merger
August 27, 2025 - - Latest News -
Mark Butler asking questions about Trump's 'Most Favored Nation' pricing push
August 27, 2025 - - Latest News